Skip to main content
Download PDF

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

Journal for ImmunoTherapy of Cancer volume 7, Article number: 73 (2019) Cite this article

The Original Article was published on 22 October 2018

Correction to: Journal for ImmunoTherapy of Cancer (2018) 6:109

https://doi.org/10.1186/s40425-018-0420-0

Following publication of the original article [1], the author reported a mistake related to a percentage. In page 5 the sentence “Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (0.3%) had progressive disease, and in three patients (9.1%), response was undeterminable.” should be replaced with “Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (3.0%) had progressive disease, and in three patients (9.1%), response was undeterminable.” (3.0% instead of 0.3%).

The publisher apologizes for any inconvenience caused by this error.

Reference

  1. Amin A, et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother Cancer. 2018;6:109. https://doi.org/10.1186/s40425-018-0420-0.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Immunotherapy program, Levine Cancer Institute, Carolinas HealthCare System, 1024 Morehead Medical Drive, Charlotte, NC, 28204, USA

    Asim Amin

  2. Division of Genitourinary Medical Oncology, Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA

    Elizabeth R. Plimack

  3. Division of Oncology, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14203, USA

    Marc S. Ernstoff

  4. Department of Medicine at The Geisel School of Medicine and The Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, NH, 03756, USA

    Lionel D. Lewis

  5. Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN, 37203, USA

    Todd M. Bauer

  6. Department of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA, 02215, USA

    David F. McDermott

  7. Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 21287, USA

    Michael Carducci

  8. Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, V5Z 4E6, Canada

    Christian Kollmannsberger

  9. Lerner College of Medicine, Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, 44195, USA

    Brian I. Rini

  10. Department of Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, AB, T2N 4N2, Canada

    Daniel Y. C. Heng

  11. Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, Toronto, ON, M5G 1Z5, Canada

    Jennifer Knox

  12. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA

    Martin H. Voss

  13. Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, T6G 1Z2, Canada

    Jennifer Spratlin

  14. Oncology - Global Clinical Research, Bristol-Myers Squibb, Princeton, NJ, 08541, USA

    Elmer Berghorn & Lingfeng Yang

  15. Department of Internal Medicine, UT Southwestern – Kidney Cancer Program, Dallas, TX, 75390, USA

    Hans J. Hammers

Authors
  1. Asim Amin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth R. Plimack
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marc S. Ernstoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lionel D. Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Todd M. Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David F. McDermott
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Michael Carducci
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christian Kollmannsberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Brian I. Rini
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Daniel Y. C. Heng
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jennifer Knox
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Martin H. Voss
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Jennifer Spratlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Elmer Berghorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Lingfeng Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Hans J. Hammers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Asim Amin.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Amin, A., Plimack, E.R., Ernstoff, M.S. et al. Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. j. immunotherapy cancer 7, 73 (2019). https://doi.org/10.1186/s40425-019-0559-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40425-019-0559-3